Epi One, a trailblazer in cancer diagnostics, is thrilled to announce the successful conclusion of its equity crowdfunding campaign on StartEngine, which raised an impressive $2.1 million. The campaign, which closed on December 5th, attracted strong support from individual investors inspired by Epi One’s mission to revolutionize early cancer detection.
“We are beyond grateful for the incredible support we’ve received during this campaign,” said Michael Marquardt, CEO of Epi One. “Raising $2.1 million is a testament to the trust and enthusiasm our investors have in our vision to transform cancer diagnostics and save millions of lives. This milestone marks a significant step forward in our journey to make a profound impact on global health.”
Epi One’s innovative diagnostic platform uses a simple blood test to detect DNA-based biomarkers, delivering highly accurate results in as little as six hours. This groundbreaking approach has the potential to change the way cancer is diagnosed, enabling early treatment and improving survival rates.
The $2.1 million raised through equity crowdfunding complements the $3.1 million previously secured in angel funding, bringing Epi One’s total funding to $5.2 million. These resources will be instrumental in completing clinical validation of the testing platform for additional cancer types, scaling laboratory capabilities, and accelerating efforts to bring this life-saving technology to market.
“The overwhelming response to our campaign highlights a shared belief in the urgency of addressing cancer through innovative solutions,” Marquardt added. “We’re excited to move forward with the support of our investors, who have joined us in our mission to revolutionize cancer diagnostics and improve health outcomes worldwide.”
